Guide

When Your Plan Drops GLP-1 Coverage: What Changes and What You Can Do

Formulary exclusions mid-year and at renewal have become common as GLP-1 spending has risen. An exclusion is different from a denial — the drug is off the list rather tha

Exclusion is not denial

A denial says this drug is not approved for you. An exclusion says the plan does not cover this drug at all, or does not cover this category. The appeal routes differ, and confusing the two wastes the window in which you can act.

Against an exclusion, the usual routes are a formulary exception request, a continuity-of-care provision if you were already established on the drug, or a switch to a covered alternative.

Why this keeps happening

GLP-1 spending has risen sharply, and plan sponsors have responded by excluding the weight-management indication while retaining diabetes coverage for the same molecules. Some large pharmacy benefit managers have made high-profile exclusion decisions that moved millions of members at once.

That pattern matters practically: the exclusion is frequently about the indication rather than the drug, so a qualifying comorbidity can reopen coverage under a different code.

The three routes

Formulary exception. A request that the plan cover a non-formulary drug for you specifically, usually requiring documentation that covered alternatives are unsuitable, contraindicated or have failed. This is the main route and it is a documentation exercise, like prior authorization.

Continuity of care. Many plans have provisions for members already stabilised on a therapy when coverage changes, often granting a transition period. This is time-limited and you must ask — it is rarely applied automatically.

Covered alternative. If a different GLP-1 remains on formulary, switching may be the fastest route. That is a clinical decision, and switching between these drugs is not dose-for-dose.

What to establish immediately

1. Is the exclusion the drug, the category, or the indication?
2. Is any GLP-1 still covered, and for which indication?
3. Does the plan have a continuity-of-care provision, and what is the window?
4. What does the formulary exception process require, in writing?
5. When does the exclusion take effect — immediately, at refill, or at renewal?

The last one sets your timeline and is the one most often assumed rather than checked.

If none of it works

The self-pay landscape has changed materially. Brand Zepbound is $299 to $449 direct from LillyDirect. Both approved oral GLP-1s start at $149. Eligible Medicare enrollees pay $50 through the GLP-1 Bridge.

Those figures are considerably better than the position two years ago, when list prices above $1,000 made compounded products the only realistic route for uninsured patients. Sixteen compounded offerings in our dataset now cost more than brand Zepbound's starter rate.

The thing worth doing before the change lands

If you have notice of an exclusion at renewal, start the exception request before coverage ends rather than after. The process takes weeks, and beginning it while you are still covered avoids the gap entirely.

Questions readers actually ask